Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Relative Strength Index (RSI) is 30.12, with weekly volatility at 6.08% and ATR at 0.72. The AERI stock’s 52-week price range has touched low of $10.80 and a $26.26 high. Intraday shares traded counted 0.77 million, which was 11.21% higher than its 30-day average trading volume of 872.01K. Its shares traded lower over the last trading session, losing -1.18% on 07/30/20. The shares fell to a low of $11.37 before closing at $11.73. AERI’s previous close was $11.87 while the outstanding shares total 45.79M. The firm has a beta of 0.99.
Investors have identified the Drug Manufacturers – Specialty & Generic company Aerie Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $564.33 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Aerie Pharmaceuticals Inc. (AERI) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For AERI, the company has in raw cash 134.18 million on their books with 5.61 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 338437000 million total, with 79145000 million as their total liabilities.
AERI were able to record -43.06 million as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by -9.76 million. In cash movements, the company had a total of -41.82 million as operating cash flow.
Potential earnings growth for Aerie Pharmaceuticals Inc. (AERI)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Aerie Pharmaceuticals Inc. recorded a total of 20.34 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 46.65% coming in sequential stages and their sales for the third quarter reducing by -21.22%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 6.09 million trying to sell their products during the last quarter, with the result yielding a gross income of 14.25 million. This allows shareholders to hold on to 45.79M with the revenue now reading -1.07 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.75 cents a share).
Having a look at the company’s valuation, the company is expected to record -3.40 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on AERI sounds very interesting.
Is the stock of AERI attractive?
In related news, Director, Cagle Gerald D. sold 5,000 shares of the company’s stock in a transaction that recorded on May 08. The sale was performed at an average price of 15.27, for a total value of 76,350. As the sale deal closes, the 10% Owner, Foresite Capital Management II now sold 1,000,000 shares of the company’s stock, valued at 17,070,000. Also, Chief Financial Officer, RUBINO RICHARD J bought 5,040 shares of the company’s stock in a deal that was recorded on Sep 09. The shares were price at an average price of 19.93 per share, with a total market value of 100,447. Following this completion of acquisition, the Chief Executive Officer, ANIDO VICENTE JR now holds 26,250 shares of the company’s stock, valued at 498,953. In the last 6 months, insiders have changed their ownership in shares of company stock by 2.10%.